# An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

> **NCT06693973** · EARLY_PHASE1 · RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 13 (estimated)

## Conditions studied

- B-cell Non-Hodgkin Lymphoma (B-NHL)

## Interventions

- **DRUG:** AcNK-Sup003 cell injection solution

## Key facts

- **NCT ID:** NCT06693973
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-27
- **Primary completion:** 2026-01-13
- **Final completion:** 2026-01-13
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2024-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06693973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06693973, "An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06693973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*